BioSpace News Archive

BriaCell Therapeutics Corp., a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has been selected to present at the 2020 ASCO Annual Meeting, a virtual event held during the dates of the originally planned in-person Annual Meeting.

China Pharma Holdings, Inc., an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, announced financial results for the fiscal year ended December 31, 2019.

First AI-powered FOLFOX predictor to guide first-line metastatic colorectal cancer treatment

BX001 demonstrates excellent safety, tolerability, and a statistically significant reduction of C. acnes levels on skin

Company Has Launched Five Products in Last Three Months

BioNTech SE, a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and infectious diseases, provided an update on its corporate progress and reported financial results for the quarter and full year ended December 31, 2019.

Anavex Life Sciences Corp. provided an update on the evolving COVID-19 condition and the Company’s response to its clinical program development.

Amarin Corporation plc (NASDAQ:AMRN), hosted a webcast yesterday to discuss important data with study authors who presented at the American College of Cardiology’s 69 th Annual Scientific Session Together With World Congress of Cardiology (ACC.20/WCC), March 28-30. The data presented related to VASCEPA® (icosapent ethyl) capsules, the landmark clinical outcomes study REDUCE-IT®, as well as persistent cardiovascular risk

Progressive Care Inc., a personalized healthcare services and technology company, is very excited to announce the release of the Company’s audited Annual Report for 2019.

GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with its U.S. subsidiary Greenwich Biosciences, Inc., today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing with Priority Review its recently submitted supplemental New Drug Application (sNDA) for the use of EPIDIOLEX ® (cannabidiol) CV to treat seizures a